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Summary 
Factor B (Bf), an enzyme of the alternative pathway of complement activation, is one of four 
major histocompatibility complex (MHC) class III genes. To ascertain the genetic mechanism 
for tissue-specific constitutive and regulated expression of Bf, we sequenced the regulatory regions 
5' of the gene from mice of different H-2 MHC haplotypes and assessed trans-acting  factors, 
specific DNA binding nucleoproteins, in liver and kidney. Striking tissue-specific differences in 
constitutive expression  of Bf were demonstrated in mice of H-2  f or H-2  z haplotypes when 
compared with H-2  a or H-2 u (kidney and intestinal Bf in H-2 a or H-2 u >> H-2  f or H-2z). These 
differences correlated with a point nucleotide substitution 3 bp downstream of the upstream 
Bf initiation site that affects interaction with a DNA binding protein. This and additional c/s 
differences localize  the sequence substitutions responsible  for previously identified restriction 
fragment length polymorphisms among inbred mouse strains  and also reveal two previously 
unrecognized polymorphisms generated by SmaI and Hinfl digestion. Evidence for differences 
in tram was found in a comparison of DNA binding nucleoproteins from kidney, but not liver, 
of B10.PL when compared with B10.M. These data, together with the high degree of sequence 
homology between human and mouse Bf 5'  flanking regions,  should prompt a  search for 
polymorphic restriction sites and cis binding elements in the Bf promoter that could serve as 
markers of human MHC-associated renal pathology and variants  in local MHC class III gene 
expression. 
F 
~actor B (Bf), 1 a 93-kD single chain glycoprotein serine 
proteinase,  is a constituent of the antibody-independent 
alternative pathway of complement activation, an important 
mechanism for  host  defenses  against  microbial  infection 
(reviewed in reference 1). In addition, Bf activation cleavage 
products affect B lymphocyte proliferation and differentia- 
tion (2, 3), and participate in monocyte-mediated  cellular cy- 
totoxicity (4-6) and macrophage spreading (7). The Bf gene 
is located within the MHC, immediately 3' to the homolo- 
gous complement gene C2 on chromosome 6 in humans (8) 
and 17 in mice (9, 10). Bf is synthesized in liver (11), hepa- 
toma cells (12), and at many extrahepatic sites (13), in mono- 
nuclear phagocytes (14, 15), fibroblasts (16), endothelial (17), 
and epithelial (18) cells. The expression of Bf is upregulated 
by bacterial products (endotoxin) (19) and by several cytokines, 
including Ibl (20, 21), Ib6 (22), TNF-c~ (23),  and IFN-3' 
(24). A map of the sequence 5' to the Bf gene and extending 
into the 3' untranslated region of C2 gene has revealed do- 
mains necessary for constitutive and IL-1- and IFN-3,-regulated 
expression  (25-27). 
1  Abbreviations  used in thispat~'r: Bf, factor B; SAA, serum amyloid A; UIS, 
upstream  transcriptional  initiation site. 
Among inbred mouse strains, differences in Bf serum con- 
centrations are paralleled by differences in hepatic Bf mRNA 
expression (28). Constitutive expression of Bf is tissue specific 
within a given strain.  That is, hepatic Bf mRNA in mice 
of H-2  u strains is greater than in H-2  d or H-2  f. On the other 
hand, in H-2  a peritoneal macrophages, Bf mRNA is greater 
than in either H-2 u or H-2  f strains. Moreover, in kidney and 
small intestine, two Bf transcripts resulting from utilization 
of alternative sites of transcriptional initiation (302 bp from one 
another) (29) are expressed in approximately equal amounts, 
but in liver, the Bf long mRNA represents <5% of mature 
Bf transcripts (30).  The purpose of the present study was 
to identify and elucidate the relative importance of cis- and 
trans-regulatory  elements on this strain-  and tissue-specific 
expression  of Bf. 
Materials and Methods 
M~e  6-8-wk-old  male mice  ofBALB/cJ,  B10.D2/nSnJ, B10.PL 
(73NS)/Sn, B10.M/Sn, NZW/LacJ, and A.CA/Sn strains were pur- 
chased from The Jackson Laboratory (Bar Harbor, ME). 
RNA Isolation and Analysis.  Mice  were injected  intraperitoneally 
with 200 #1 of saline alone, saline containing 10/~g of sonicated 
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Chemical Co., St. Louis, MO), or were uninjected. The animals 
were killed by cervical dislocation 24 h. later; liver, kidney, and 
small intestine were immediately removed, cleaned, snap frozen in 
liquid nitrogen,  and stored at  -70~  The frozen tissues were 
pulverized in liquid nitrogen, and total RNA was extracted  by lysis 
with guanidinium thiocyanate  and cesium chloride density gradient 
ultracentrifugation (31). RNA was quantitated by absorbance at 
260 nm. 
RNA samples (10/~g) were denatured and subjected to elec- 
trophoresis in formaldehyde-containing  1% agarose gels as previ- 
ously described (32). The gels were rinsed overnight and I~NA 
was transferred  to nitrocellulose  sheets (Bio-Rad  Laboratories,  Rich- 
mond, CA). The membrane were baked, prehybridized, and hy- 
bridized overnight at 65~  with the appropriate cDNA probe in 
5x  SSC, 0.2%  Ficoll 400, 0.2%  BSA, 0.2%  polyvinyl pyrroli- 
done, 0.2% SDS, 0.05% Na pyrophosphate,  0.1 mg/ml boiled soni- 
cated salmon sperm DNA, pH 6.5. The blots were washed twice 
at 65~  in 0.2x  SSC, 0.2%  SDS, and exposed to x-ray film at 
-70~  using an intensifying screen. 
The probes were radiolabeled (33) with 100/~Ci of t~-[3~p]dCTP 
(New England Nuclear, Boston, MA), using the Random Primed 
DNA Labeling Kit (Boehringer-Mannheim Biochemicals, Indi- 
anapolis, IN) according to the manufacturer's protocol. For Bf and 
serum amyloid A (SAA) cDNA probes, the 2-kb EcoRI fragment 
from pmBfS/70 clone (30) and the 195-bp PstI fragment from pal 
clone (34), respectively,  were used as template. To detect Bf long 
mRNA, the RNA probe (-269 to  -48 of Bf short) previously 
described (29) was generated using ct-[32P] CTP (New England 
Nuclear) and the SP6-T7 transcription kit (Boehringer-Mannheim 
Biochemicals). With this probe, 50% deionized formamide was 
added to the hybridization solution. 
PCR Amplification, Cloning~ and Sequencing of the Murine C2-Bf 
Intergenic Region.  High molecular  weight DNA was prepared from 
mouse liver  as described (35). The genomic segment - 724 to + 118 
(nucleotide positions relative to the downstream Bf cap site) from 
each strain was amplified  by a 30-cycle Taq PCR (36) from 1/~g 
of DNA in a TempCycler  (Coy Laboratory Products, Ann Arbor, 
MI), using the GeneAmp  DNA Amplification  Reagent Kit (Perkin 
Elmer Cetus, Norwalk, CT), as described in the manufacturer's 
protocol. The primers, designed from the previously  published se- 
quences (25, 30), included a 26-base genomic sequence (-724 to 
-699 of the coding strand and  +118 to  +93 of the noncoding 
strand) flanked  with XhoI (coding strand primer) and BgllI (non- 
coding strand primer) cloning sites. The conditions for denatura- 
tion, annealing, and polymerization were 2 rain at 950C, 2 min 
at 65~  and 5 min at 72~  respectively. The first denaturation 
step was extended to 5 min, and after the last cycle, the synthesis 
was completed by an additional 7-rain incubation step at 72~ 
The PCIL product was digested with XhoI and BgllI, gel purified, 
and cloned  into pSP72 (Promega  Biotec, Madison,  WI). The plasmid 
was then purified (37) and the sequence  determined on both strands 
after alkaline  denaturation (38) by the dideoxy-termination  method 
(39), according to the manufacturer's protocol (Sequenase Version 
2.0 Kit; United States Biochemical Corp., Cleveland, OH). 
The sequence differences  among strains were confirmed by di- 
rect sequencing and restriction mapping (Sinai, Hinfl, HindlII, 
KpnI) in several PCR reactions. For each strain, three to five  PCR- 
generated clones were mapped and interstrain mutations  were 
confirmed in duplicate clones. Direct sequencing  of the PCR prod- 
ucts were performed with slight modification: the annealing mix- 
ture, containing 1 pmol of the gel-purified DNA and 1 pmol of 
primer, was heat denatured in boiling water for 7 min, cooled to 
room temperature for 1 rain, transferred to ice, and labeled for 3 
rain, using half the amount of unlabeled nucleotides as for cloned 
DNA. Annealing and labeling  reactions  were performed  in the pres- 
ence of 10% (vol/vol) DMSO. 
GelRetardation Assay.  Nuclei  were freshly  prepared from mouse 
tissues as described  (40), lysed  with NaC1 and spermidine (41), and 
the resulting extracts dialyzed  overnight (42). The soluble fraction 
was measured for protein content (43) and stored at  - 70~  The 
binding reaction (25/~1) was performed with 8 ~1 (4/~g) of nuclear 
extract, 1 ng/200 bp of end-labeled probe, and 1/~g of poly[dI- 
dC]-poly[dI-dC] (Sigma Chemical Co.), in a buffer containing 10 
mM Tris-HC1, 50 mM NaC1, 5% glycerol, 1 mM EDTA, 1 mM 
DTT, 1 mM PMSF, pH 7.5. After 20 rain at room temperature, 
a bromphenol  blue/xylene  cyanol  solution was added  and electropho- 
resis carried out in 4.5% polyacrylamide  gel in lx  TAE (40 mM 
Tris acetate, 1 mM EDTA, pH 8.0) at 4~  The gel was fixed, 
dried, and exposed at  -70~  to x-ray  film, using an intensifying 
screen. Probes were end labeled  using Klenow enzyme (Boehringer 
Mannheim Biochemicals) and ol-[32p]dCTP (New England Nu- 
clear). Competition experiments were performed with 50 times 
molar excess of unlabeled DNA fragments. The probes, generated 
from restriction fragments, and competitors consisting of restric- 
tion fragments  or PCR-amplified  segments or annealed  complemen- 
tary oligonucleotides,  are described  in Results. PCR segments  were 
synthesized  as above, but using 18-met primers and the XhoI-BglII 
cloned fragment (see above) as template. 
Results 
Strain- and Tissue-specific Variation in Bf mRNA Content.  Bf- 
specific mR.NA content of liver, kidney, and small intestine 
from mice of BALB/c (H-2  d haplotype),  B10.D2  (H-2d), 
B10.PL (H-2u), B10.M (H-2f), and NZW (H-2  z) strains was 
estimated by Northern blot analysis. The results of one of 
the replicate (up to four mice of each strain and multiple RNA 
determinations from each) experiments are shown in Figs. 
1 and 2. Constitutively, approximately equal amounts of two 
distinct Bf mRNA species (2.4 and 2.7 kb) were present in 
kidney of strains of the H-2  a and H-2  u haplotypes, whereas 
no Bf message was detected in strains of the H-2  f or H-2  z 
haplotype (Fig.  1 A). After LPS injection, in the strains ex- 
pressing detectable kidney Bf mRNA,  the content of the 
shorter message (Bf short) increased, while the longer tran- 
script  (Bf long)  slightly decreased.  The rank order of Bf 
mlkNA level among these strains was: BALB/c <  BI0.D2 
<  B10.PL.  In B10.M and NZW strains,  even the Bf short 
mRNA was barely detectable after LPS injection. 
Small intestine contained both Bf  mRNA species in B10.D2 
(Fig. 1 B), BALB/c, and B10.PL (not shown). Bflong mRNA 
was more abundant than Bf short; as in kidney, the latter 
increased after LPS administration. NZW and B10.M intes- 
tine failed to express Bf mRNA constitutively, and minimal 
amounts of Bf short were detected after LPS stimulation. 
The difference in kidney Bf mRNA between B10.M or 
NZW and the other strains was not paralleled by differences 
in liver Bf mRNA among the corresponding strains  (Fig. 
2). Indeed, hepatic Bf mRNA was constitutively expressed 
and upregulated by LPS in all strains  examined (Fig.  2 A). 
While the constitutive level of liver Bf mRNA showed minor 
strain-specific variation (the rank order was: B10.M ~  B10.D2 
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and (B) small  intestine. Total  RNA was isolated  from tissues of various 
strains 24 h after  intraperitoneal  injection  of saline (-) or 10/~g of LPS 
(+), subjected  to electrophoresis  in agarose  gel (10 #g of RNA per lane), 
transferred to a nitrocellulose  membrane, and probed with a 2-kb cDNA 
sequence  spanning  up to the 3' end of  the transcripts  (top). (Bottom)  Ethidium 
bromide stain of the gels is shown. 
~BALB/c <NZW <B10.PL), no significant difference was 
found among the LPS-treated animals, except for NZW, for 
which the upregulated level was lower than in the other strains. 
The induction of hepatic SAA mRNA, used as an index for 
the LPS response,  was similar in all strains (Fig. 2 A). Anal- 
ysis of Bflong mRNA with a 5' probe that does not overlap 
Bf short mRNA sequence shows that, in contrast to kidney, 
the constitutive hepatic expression  of the long message was 
similar in B10.PL and in B10.M (Fig. 2 B). Constitutive ex- 
pression of Bf mRNA in all tissues  examined was similar 
in A.CA and B10.M strains that share  the H-2  f haplotype 
but differ in background (A/Wy instead of C57BL/10). A 
comparison between BALB/c and A.CA is shown in Fig. 3. 
Within each strain the constitutive level of  BfmRNA in saline- 
injected mice was indistinguishable from that of untreated 
animals (not shown). 
Strain-specific Sequences of the 5' Flanking Region of Factor 
B Gene.  For nucleotide sequencing of the upstream region 
of  Bf (-698 to + 92) in the different mouse strains, the -724 
to  + 118 genomic segments (nucleotide numbering refers to 
the downstream initiation site of transcription),  encompassing 
the 3'-untranslated region of C2 gene and the 5'-untranslated 
region of C2 Bf gene, were amplified by PCR. The differ- 
ences among the six strains are shown in Fig. 4. In the strains 
with H-2  d (BALB/c,  B10.D2)  or H-2  u (B10.PL)  haplotype 
(group I), the sequences were identical to previous reports 
(25, 30).  The strains B10.M and A.CA shared the same se- 
quence (group II); a sequence that differed from the first group 
in four regions (Fig. 4, A, B, C, and D). At position  -553 
(A), a point substitution (G---A) abrogates an SmaI restric- 
tion site. Next to the upstream transcriptional initiation site 
(-302; B), three point substitutions were found at positions 
-327 (T~C, which abrogates a Hinfl restriction site),  -307 
(G~A), and  -299 (T--~C, which generates a HinfI restric- 
tion site). In strains of group II, the segment - 203 to - 198 
(C), corresponding to the sequence AGGGAG in the group 
I, is deleted. This deletion generates a HindlII restriction site. 
Two point substitutions (D)  were found at positions  +22 
Figure 2.  Hepatic  Bf gene expression among  strains. (/1) Constitutive 
(-) and LPS-regulated  (+) expression of Bf mRNA; same protocol as 
in Fig. 1. Liver  Bf mRNA was probed along  with SAA mRNA as a con- 
trol for the hepatic response to LPS. (B) Constitutive  expression of Bf 
long  mRNA in B10.PL  (PL) and B10.M (M) liver  (and  kidney  as control). 
In this experiment, Bf long was specifically  detected  by an RNA probe 
from a genomic  sequence 5' to the transcription start site for Bf short. 
(G~A) and + 52 (C~T, which generates a KpnI restriction 
site in group II). NZW (H-2  z) was included in group II be- 
cause  the sequence  is identical to that for the H-2  f haplo- 
type, except that the nucleotide at position  + 52 (/9) is not 
substituted. 
Interactions between Sequences Upstream to Bf  Gene and Mouse 
Liver and Kidney Nuclear  Factors.  Nuclear extracts as a source 
of DNA-binding factors were prepared from liver and kidney 
of  untreated B10.PL and B10.M strains. BfmRNA was moni- 
tored by Northern blot analysis in the same animals for each 
tissue studied to assure that the extracts were obtained from 
tissues expressing Bf  constitutively. Four overlapping genomic 
fragments (designated fragments A, B, C, and D) encom- 
passing the intergenic region between murine C2 and Bf (from 
the last exon of C2 to the first exon of Bf) were generated 
(Fig.  5)  from group  I  (H-2  d,  H-2  u)  and  group  II  (H-2  f, 
Figure 3.  Constitutive  Bfgene 
expression  in A.CA  strain. A com- 
parison of Bf  mR.NA from small 
intestine  (SI),  kidney  (K), and liver 
(L) of untreated mice  of BALB/c 
and A.CA  strains  (first  and second 
lane  of  each  pair, t~spectively)  was 
assessed  by Northern  blot analysis 
(top) using the same probe as in 
Fig. 1. (Bottom)  Ethidium  bromide 
stain of the gd is shown. 
473  Gamier  et al. Figure 4.  Sequence  polymorphism  in the 5'-flanking  region of murine Bf gene. For each of the six strains studied, the -698 to  +92 (+1 is the 
transcription start site for Bf short) genomic  segment was PCR amplified,  cloned, and the nucleotide  sequence determined. (.4, B, C, and D) The 
four areas of representative sequencing  gels (coding strand) presenting  differences  among strains. Their relative  positions are indicated  in the bottom 
and aligned  with the main features  of the C2-Bf  genomic  region. The strains were split into two groups according  to the sequence. Group I (BALB/c, 
B10.D2, and B10.PL) and group II (B10.M, A.CA, and NZW) -specific  nucleotides  are shown above and under the line, respectively.  "The difference 
between NZW and the other group II strains at + 52 (D) with a cytosine  (like group I) instead  of a thymidine.  The positions of the upstream (UIS, 
at -302), and downstream  (DIS, at + 1) transcriptional  initiation  sites for Bf long and short mRNAs, respectively,  are indicated. The C2 stop codon 
(Stop) and polyadenylation  site (PolyA),  the interleukin 1 (II:1), and IFN-3'  ORS) response  elements  for Bf  gene, and the putative  Bf  TATA  box (CATAAA) 
and first methionine (Met) are also represented. 
H-2  z) clones (see paragraph above) and labeled for use in gel 
retardation assays. 
Two regions of major sequence-specific  interaction were 
found in group I sequence for B10.PL liver and kidney factors, 
as demonstrated by retardation of probes B and D and com- 
petition with the respective unlabeled fragments (Fig. 5). With 
either probe B or D, the major complexes formed in the pres- 
ence of kidney extracts had the same mobility as with liver. 
Fragments A and C showed much lesser binding activity with 
either tissue and no difference  was found using the corre- 
sponding sequences of group II nor with B10.M extracts (not 
shown). 
To assess whether strain-specific  nuclear elements (DNA 
or proteins) participate in cis  or in tram to the interactions 
with fragments B and D, liver and kidney extracts from B10.PL 
and B10.M strains were probed with fragments B and D of 
group I and group II sequences  (Fig.  6). 
As shown in Fig. 6 A, when fragment B (which includes 
the upstream transcription start site) of group I sequence was 
used as a probe, one or two major complexes were formed 
with liver and kidney nuclear factor(s) from each strain. Two 
distinct retarded bands were clearly visible when kidney ex- 
tracts from either strain were used. In all cases, the sequence 
specificity of the interaction was demonstrated by competi- 
tion with excess of unlabeled probe.  Using fragment B of 
group II sequence as a probe, no major retarded band could 
be detected in the presence of liver or kidney extracts from 
either strain. The interaction at fragment B of group I was 
only partially competed by an excess of unlabeled fragment 
B of group II (Fig. 7 A, lane 4). A 35-mer double-stranded 
synthetic oligonucleotide defined by group I sequence, namely 
Bsl (-323 to  -289, with G at  -307 and T  at  -299), en- 
compassing Bf upstream transcriptional initiation site (UIS; 
at  -302),  was able to compete for this interaction (Fig.  7 
C, lane 4) and to form a major specific complex with liver 
and kidney extracts when used as a probe (not shown). A 
series of oligonucleotides with combinations of substitutions 
at  -307 and  -299,  namely Bs2 (A and C  =  group II se- 
quence),  Bs3  (A and T),  and Bs4  (G and C), were tested 
as competitors against group I fragment B as a probe for 
binding liver extracts (Fig. 7 C). Partial competition was ob- 
served with Bs2 and Bs4, whereas Bs3, like Bsl, completely 
competed for the interaction. The same observations were 
made  with  kidney extracts  (not  shown).  Therefore,  the 
T --~ C substitution at - 299 observed in group II strains and 
located 3 bp downstream from the UIS prevents the interac- 
474  cis and trans  Elements in Factor B Expression Figure 5.  Interactions  of liver and kidney  constitutive  nuclear factors 
along the Bf gene promoter region. Nuclear extracts from liver (lanes 2 
and 4) and kidney  (lanes 3 and 5) of untreated B10.PL mice  were probed 
for gel retardation with (A) XhoI-AspHI (-727  to  -449), (/3) Avall- 
Dral (-502 to -262), (C) NcoI-PstI (-281 to -49), and (D) PvulI-BgllI 
(-118 to + 116) genomic  restriction fragments  of the group I sequence 
(BALB/c, B10.D2, and B10.PL). (Lane 1) Probe alone; (lanes 2 and 3) 
binding assay; (lanes 4 and 5) binding assay  in the presence of a 50-fold 
molar excess of cold probe. The four fragments,  designated  A, B, C, and 
D, are depicted relative to Bf transcription start sites (UIS and DIS). 
tion of a c/s element, located within the Bs segment (-323 
to -283), with one or more sequence-specific nuclear factors 
constitutively expressed  in liver and kidney of B10.PL and 
B10.M strains. 
Using fragments D  of group I (H-2  d, H-2  u) and group 
II (H-2  f) sequences  as probes and the same nuclear extracts 
from B10.PL and B10.M strains as above, the gel retardation 
patterns were similar for each probe and each tissue (Fig.  6 
B). However, the intensity of the three major retarded bands 
was significantly  lower with B10.M than with B10.PL kidney 
extracts. The major retarded bands using liver extracts from 
either strain and each kidney extract were quantitatively similar 
irrespective  of the probe.  Competition with the unlabeled 
probes indicated that the corresponding interactions were se- 
quence specific. Four subsegments of fragment D  of group 
I  sequence  (namely D1,  D2,  D3,  and D4)  were generated 
by PCR and tested as competitors to localize the interaction 
on fragment D (Fig. 8 B). The main retarded band was com- 
pletely competed by segment D3 (-4 to + 75) and only par- 
tiaUy by segments D2 ( - 63 to + 14) and D4 (+ 56 to + 116). 
A  50-met oligonucleotide, Ds (+33  to  +82),  overlapping 
D3 was also able to compete for the interaction (Fig.  8 C) 
and to form a major specific complex when used as a probe 
(not  shown). 
Using probes  and competitors of group I  sequence  and 
liver extracts, partial cross-competition with probe B (Fig. 
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Figure 6.  C/s and trans differences  in protein-DNA  interactions  among 
strains  in fragments  B and D. Liver  and kidney  nuclear  extracts  from  B10.PL 
(PL) and B10.M (M) strains were probed for gel retardation  with frag- 
ments B (A) and D (B) of group I (probes 1) and group II (probes 2) 
sequences. (B) Probe 2 is of the H-2  f sequence (two substitutions  vs. group 
I). CP denotes  competition  with cold  probe. The nucleotides  specific  for 
group I and group II and other features  of fragments  B and D are shown 
in Figs. 7 and 8. 
7, A  and B) was observed with fragment D  and segment 
D3. Fragments A and C and segments D1, D2, and D4 failed 
to compete with this probe.  Reciprocally,  the interaction at 
probe D  (Fig. 8 A) was partially competed with fragments 
A  and  B,  in contrast  with fragment C.  The  same  cross- 
competition phenomenon was observed using kidney extract 
(not  shown). 
Discussion 
In the present report we demonstrate that among inbred 
mouse strains,  striking tissue-specific differences in the level 
of Bf gene expression  correlate with cis differences in the Bf Figure  7.  Competition assays  for binding on fragment B by various DNA 
sequences. Gel retardations  were performed  using fragment  B of group 
I sequence as a probe and B10.PL liver nuclear extract.  (A) Competition 
with fragment  B of group I (lane 3) and group II (lane 4) sequences and 
fragments  A, C, and D  (lanes 5, 6, and 7, respectively) (see Fig. 5) of 
group I. (Lane I) Probe alone; (lane 2) no competitor.  (B) Competition 
assays with subfragments of fragment D (group I sequence). (Lane I) no 
competitor;  (lanes 2, 3,  4,  and 5) competition with D1, D2, D3, and 
D4, respectively (see Fig. 8). (C) Localization of the binding site of frag- 
ment B and identification  of the base substitution  affecting it in group 
I1. (Lane I) Probe alone; (lane 2) no competitor;  (lane 3) competition with 
cold probe; (lane 4, 5, 6, and 7) competition with double-stranded oligo- 
nucleotides Bsl (G at  -307, T at  -299), Bs2 (A,C), Bs3 (A,T), and Bs4 
(G,C), respectively. The representation of fragment B shows group I- and 
group ll-specific  nucleotides  (T,G,T and C,A,C, respectively) at  -327, 
-307, and  -299, and the position of the UIS (-302) and of the oligonu- 
cleotides (oligo  Bs) used in  C. 
Figure 8.  Competition assays for binding on fragment D. Gel retarda- 
tion assays were performed with probe D and B10.PL extract. Probe and 
all competitors  were of group I sequence. (A) Competition with frag- 
ments  A, B, and C  (lanes 4,  5,  and 6,  respectively) (see Fig. 5).  (Lane 
I) Probe alone; (lane 2) no competitor;  (lane 3) competition with cold 
probe. (B and C) Localization of the binding site of fragment D. (B) (Lanes 
1-3) Same as in A; (lanes 4, 5, 6, and 7) competition with D1 (-86 to 
- 43), D2 (- 63 to + 14), D3 (- 4 to + 75), and D4 (+ 56 to + 116), respec- 
tively. (C) (Lane I) No competitor;  (lane 2) competition with oligonucle- 
otide Ds (+33 to  +82).  Fragment D is depicted along with competitors. 
Group I- and H-2~-spedfic nucleotides (G,C and A,T, respectively) and 
DIS (at  +1)  are indicated. 
gene 5' regulatory region. These include a point substitu- 
tion, 3 bp from the transcription start site for Bflong mRNA, 
affecting the binding activity of a cis element for a constitu- 
tive,  sequence-specific nuclear factor(s). 
In the past few years, the importance of extrahepatic com- 
plement synthesis in the local inflammatory process has been 
increasingly exemplified by the ubiquity of cytokine-induced 
complement production (16, 17, 21, 23, 24, 28), and partic- 
ularly emphasized in murine models of SLE by the observa- 
tion that several complement genes are upregulated at sites 
of inflammation concomitant with the development of the 
disease (44,  45).  Increasing evidence was also accumulated 
that the control of constitutive and regulated expression of 
complement genes in extrahepatic tissues is independent from 
that in liver. This concept was illustrated in a study reporting 
quantitative tissue-specific  differences for Bf,  C3,  and C2 
mRNAs  among  several inbred  murine  strains  (28).  By 
analyzing Bf mRNAs in tissues and strains displaying quan- 
titatively more profound differences, we provide evidence that 
pretranslational, tissue-specific mechanisms controlling con- 
stitutive and LPS-regulated expression  of Bf gene differ in 
inbred strains carrying H-2  f or H-2  z haplotype, when com- 
pared with H-2  d and H-2  u. That is, in kidney and small in- 
testine,  both Bf short and long mRNAs are constitutively 
expressed at relatively high levels in BALB/C, B10.D2 (both 
H-2a),  and B10.PL  (H-2~), but are nearly undetectable in 
B10.M,  A.CA (both H-2f),  and NZW  (H-2z);  this differ- 
ence was maintained even after LPS stimulation. In contrast, 
the difference in hepatic expression of Bf is quantitatively  less. 
Several lines of evidence support the hypothesis that the 
strain- and tissue-specific Bfexpression originates in part from 
a  cis regulatory element at the transcriptional initiation site 
for Bf long mRNA. The parallel between Bf gene expres- 
sion in kidney and small intestine indicates a similar tissue- 
specific mechanism generating high steady-state levels of Bf 
long mRNA in H-2  a and H-2  u strains, and a similar strain- 
specific mechanism resulting in the lower level of both Bf 
mRNAs in H-2  f and H-2  z strains.  A relationship between 
the two mechanisms is strongly suggested by the observa- 
tion that the strain-specific expression (a) is also tissue-specific 
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mRNA transcriptional initiation site. The point substitution 
located 3 bp downstream of this transcription start site is 
the only cis difference within a 790-bp genomic segment en- 
compassing the end of C2 gene and Bf 5' untranslated region 
that affects a DNA-protein interaction. This genomic region, 
previously sequenced in H-2  a strains (25, 30), includes a pro- 
moter activity, functional II.-1 and IFN-y response elements 
(25, 26), and both transcription start sites (29), and therefore 
represents an essential c/s component in the control of Bf gene 
expression. Moreover, the corresponding human genomic re- 
gion was found to contain an enhancer activity that could 
contribute to the cell-type specificity of Bf gene expression 
(27). Because the Bf gene is located within the S region of 
the H-2 complex (9, 10), the correlation between strain-specific 
Bf expression  and H-2 haplotype reinforces  the possibility 
that the strain-specific expression originates from a cis regula- 
tory element of the Bf gene itself. Similarities in Bf expres- 
sion among strains  that differ genetically including in the 
H-2  complex (NZW,  compared with  B10.M  or  A.CA; 
BALB/C, compared with B10.PL),  but share the same c/s 
specificity of binding, supports this assertion.  However, the 
possibility that  strain-specific  Bf expression  could be de- 
termined in trans by H-2-dependent, tissue-specific regula- 
tory factors, or by more distal cis elements, is not excluded. 
In any case, the H-2 haplotype is most likely determinant 
since, among three H-2 congenic strains  sharing the same 
B.10 background, only the H-2  f strain (B10.M) displays low 
extrahepatic expression,  like the A.CA strain,  another con- 
genic line with H-2  f haplotype but a different genetic back- 
ground. 
The comparisons among strains  for Bf expression  and 
cis/trans  interactions show that the c/s element at the UIS, 
although not involved in the hepatic expression of either Bf 
mRNA, might be essential in kidney and small intestine. 
However, the gel retardation assays could not clearly distin- 
guish liver from kidney nuclear factors, since the interaction 
with extracts from both tissues yields a major DNA-protein 
complex of same mobility. The hypothesis that Bf tissue- 
specific expression is mediated through this interaction re- 
quires the involvement of additional trans-acting factors and 
a more complex set of protein-DNA or protein-protein in- 
teractions.  In several reported cases (46-48),  the promoter 
activation by a transcription regulatory factor does not reflect 
a change in the primary DNA protein interaction but corre- 
lates with phosphorylation of the factor already bound to 
its recognition DNA sequence. Thus, the ability of a regula- 
tory factor to bind to the c/s element is not always sufficient 
to affect transcription. Such secondary events after  DNA- 
protein interaction may not always be detectable by gel retarda- 
tion analysis. Moreover, we cannot exclude that the interac- 
tion at the UIS could involve distinct factors, or combina- 
tions of factors, of very similar structure in liver and in kidney, 
or whether differential  concentration of the same factor(s) 
could determine the tissue  specificity of Bf expression. 
The other major c/s binding element, localized downstream 
to the transcription start site for Bf short mRNA, revealed 
in kidney (but not in liver) a lower concentration or affinity 
of the sequence-specific nuclear factor(s) in B10.M as com- 
pared with B10.PL. The difference was specific for this factor 
since the same kidney extracts  showed identical patterns at 
the UIS c/s element. The role of the factors binding 3' to 
the downstream promoter and their possible association with 
H-2 remain unexplained. Nevertheless, the difference in trans 
is tissue specific and parallels the difference in Bf gene expres- 
sion among strains.  However, for reasons similar  to those 
cited above, the tissue-specific expression of Bf long mRNA 
in B10.PL cannot be assigned to this primary DNA-protein 
interaction alone.  Partial,  but reciprocal,  competition for 
binding between the regions of the upstream and downstream 
promoters in vitro could reflect protein-mediated  interactions 
between the two regions in vivo. In such a molecular inter- 
action, the binding site of the UIS could possibly be used 
in kidney to control the transcription at either initiation site, 
depending on other cell physiological  variables. It is more 
difficult to envision that the assembly of a preinitiation com- 
plex or any stable interactions at the downstream promoter 
region could allow the elongation of transcription initiated 
at the upstream promoter and be necessary to this initiation. 
Analysis of Bf mRNAs in H-2 recombinant congenic strains 
and functional transcription studies in cell-flee or transient 
transfection systems could elucidate the relative contribution 
of each binding site to the strain and tissue specificity of Bf 
gene expression, and define the promoter element(s) control- 
ling the transcription of Bf long mRNA. 
The differences observed among strains and the isolation 
of both binding sites on short synthetic oligonucleotides pro- 
vide tools to isolate and identify these specific nuclear pro- 
teins and investigate the spectrum of their target genes. Such 
studies will provide new insights in understanding the mech- 
anisms generating tissue specificity in complement gene ex- 
pression and its physiological significance in host defenses and 
immune dysfunction. 
In a murine model of SLE, the H-2  z haplotype of NZW 
is determinant in the exacerbation of the autoimmune traits 
and earlier mortality of the (NZB  x  NZW)F1 hybrids vs. 
NZB (49-51).  Interestingly, during the evolution of the dis- 
ease, C2 and Bf mRNA levels in kidney remain several fold 
lower in NZB  x  NZW than in NZB and, in contrast to 
other complement transcripts, show little or no increase (45). 
The role of local complement expression in murine SLE is 
still unclear but a low expression  at the Bf locus of H-2  z 
may contribute to such differences. 
Previous  RFLP studies  of H-2 complement genes iden- 
tiffed HindlII and KpnI polymorphisms detectable with both 
C2 and Bf cDNA probes (52, 53). Our sequence data localize 
both restriction sites and reveal in addition SmaI and HinfI 
polymorphic sites. The localization of these markers will be 
useful for further studies of the C2-Bf intergenic region and 
fine mapping of H-2 recombinant strains. Although among 
human kidney samples examined to date, a single Bf mRNA 
species has been observed (29), the high sequence homology 
with mouse in the Bf 5' region, at critical sites for promoter 
activity and regulation (25, 27), raises the possibility of similar 
477  Gamier et al. tissue-specific control mechanisms in humans and occurrence 
of  individuals with markedly decreased Bf  expression in kidney. 
A search for polymorphic restriction sites and c/s binding ele- 
merits in the human C2-Bf intergenic region could generate 
important markers of Bf local expression  for human renal 
diseases associated  with the MHC. 
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